Skip to content
10-K

Annual Report

Indaptus Therapeutics, Inc. INDP

0001493152-26-010585

← back to feed
Filed
Mar 17, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 16, 2026 2.24M sh
Shares Diluted FY 2025 · Dec 31, 2025 966.12K sh
Shares Diluted restated FY 2025 · Dec 31, 2024 334.13K sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$14.82M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$12.32M
Cash And Equivalents FY 2025 · Dec 31, 2025 $8.51M
Cash And Equivalents FY 2025 · Dec 31, 2024 $5.79M
Stockholders Equity FY 2025 · Dec 31, 2025 $3.15M
Stockholders Equity FY 2025 · Dec 31, 2024 $3.94M
Stockholders Equity FY 2025 · Dec 31, 2023 $12.08M
Current Liabilities FY 2025 · Dec 31, 2025 $6.16M
Current Liabilities FY 2025 · Dec 31, 2024 $3.39M
Current Assets FY 2025 · Dec 31, 2025 $9.31M
Current Assets FY 2025 · Dec 31, 2024 $6.62M
Total Assets FY 2025 · Dec 31, 2025 $9.31M
Total Assets FY 2025 · Dec 31, 2024 $7.34M
Eps Diluted FY 2025 · Dec 31, 2025 −$21.58
Eps Diluted restated FY 2025 · Dec 31, 2024 −$44.96
Eps Basic FY 2025 · Dec 31, 2025 −$21.58
Eps Basic restated FY 2025 · Dec 31, 2024 −$44.96
Sga Expense FY 2025 · Dec 31, 2025 $10.49M
Sga Expense FY 2025 · Dec 31, 2024 $8.11M
Rd Expense FY 2025 · Dec 31, 2025 $9.34M
Rd Expense FY 2025 · Dec 31, 2024 $7.25M
Net Income FY 2025 · Dec 31, 2025 −$20.85M
Net Income FY 2025 · Dec 31, 2024 −$15.02M
Operating Income FY 2025 · Dec 31, 2025 −$19.83M
Operating Income FY 2025 · Dec 31, 2024 −$15.37M